Qianzi Che

Qianzi Che

Auto-generated profile, based on publicly available information

Qianzi Che

Institute of Clinical Basic Medicine of Chinese Medicine, Chinese Academy of Traditional Chinese Medicine, No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing, 100700, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
MHMingzhi Hu
Mingzhi Hu
TSTian Song
Tian Song
ZGZhaoyuan Gong
Zhaoyuan Gong
QCQianzi Che
Qianzi Che
JGJing Guo
Jing Guo
BLBin Liu
Bin Liu
Background: Post–COVID-19 condition presents complex symptomatology involving multifaceted interactions, which has resulted in a current lack of comprehensive understanding of its disease trajectory. This knowledge gap significantly compromises the efficiency of symptom management and adversely affects patients’ quality of life. Objective: This study aims to comprehensively characterize the temporal evolution of post–COVID-19 condition by identifying core symptom clusters and clinical phenotypes, thereby enhancing understanding of the disease trajectory. Methods: The PubMed, Web of Science, and Embase databases were searched from December 1, 2019, to March 1, 2024. Observational studies related to the prevalence of symptoms in post–COVID-19 condition had been included. We conducted a meta-analysis to synthesize symptom prevalence across different follow-up intervals following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and used a network to explore interrelationships and co-occurrence patterns among symptoms, enabling the identification of core symptoms and changes over time. Clustering analysis was used to classify included studies into distinct clinical subtypes. Results: This study analyzed 155 sets of macrolevel data from 108 clinical studies, encompassing 63,771 patients. Fatigue was the most prevalent symptom across all 4 follow-up points (52%, 48%, 46%, and 54%). Dyspnea peaked at the third and sixth follow-ups (36% and 31%) and then declined steadily (28% and 22%). Subgroup analysis revealed that Africa reported the fewest symptoms overall, yet showed high early incidences of fatigue (68%, 95% CI 50%‐85%) and dyspnea (56%, 95% CI 15%‐98%). The Americas placed greater emphasis on symptom evolution within the first postinfection year, with notably higher prevalence of anxiety (60%, 95% CI 54%‐66%) and depression (36%, 95% CI 16%‐55%). Asia and Europe documented the most comprehensive symptom profiles, with Asia reporting lower early dyspnea rates (29%, 95% CI 18%‐40%) and Europe exhibiting more complex multisystem involvement during long-term follow-up. Network analysis showed that core post–COVID-19 symptoms evolved from early respiratory-neurological manifestations to chronic multisystem symptoms dominated by dizziness. Clustering analysis further indicated a progressive convergence of 2 initially distinct post–COVID-19 subtypes, with the acute inflammatory type becoming less prominent and gradually transitioning into a more chronic, persistent pattern. Conclusions: This study provides a comprehensive characterization of the dynamic evolution of post–COVID-19 condition symptoms and clinical subtypes, highlighting their multisystem involvement. The results reveal a progressive decline in respiratory symptoms over time, while neurological manifestations emerge as the most persistent and systemically impactful core symptoms. Our findings emphasize the need for region-specific surveillance and early warning systems informed by symptom progression patterns. By continuously monitoring the trajectories of symptom clusters, this approach offers valuable insights for identifying early warning signals and targeted intervention points in the management of postinfectious sequelae arising from future large-scale epidemics.

15 July 2025 in Neurocomputing
Verified
Journal Article
Closed access
QZQingyang Zeng
Qingyang Zeng
MYMinghui Yuan
Minghui Yuan
YSYueyang Su
Yueyang Su
JMJia Mi
Jia Mi
QCQianzi Che
Qianzi Che
JWJing Wan
Jing Wan

25 August 2025 in JMIR Medical Informatics
Verified
Journal Article
Open access
QCQianzi Che
Qianzi Che
YLYuanming Leng
Yuanming Leng
WYWei Yang
Wei Yang
XCXihao Cao
Xihao Cao
ZWZhongxia Wang
Zhongxia Wang
RWRuilin Wang
Ruilin Wang
Background: Human adenoviruses (HAdVs) and COVID-19 are prominent respiratory pathogens with overlapping clinical presentations, including fever, cough, and sore throat, posing significant diagnostic challenges without viral testing. Tongue image diagnosis, a noninvasive method used in traditional Chinese medicine, has shown correlations with specific respiratory infections, but its application remains underexplored in differentiating HAdVs from COVID-19. Advances in artificial intelligence offer opportunities to enhance tongue image analysis for more objective and accurate diagnostics. Objective: This study aims to develop and validate artificial intelligence–based predictive models using tongue image features to differentiate COVID-19 from adenoviral respiratory infections, thereby improving diagnostic accuracy and integrating traditional diagnostic methods with modern medical technologies. Methods: A total of 280 tongue images were collected from 58 patients with COVID-19, 84 patients with HAdVs, and 30 healthy controls. Deep learning methods were applied to extract tongue features, including color, coating, fissures, papillae, tooth marks, and granules. Four machine learning classifiers, logistic regression, random forest, gradient boosting model, and extreme gradient boosting, were developed to differentiate COVID-19 and HAdV infections. The key features identified by the machine learning algorithms were further visualized in a 2D space. Results: Nine tongue features showed significant differences among groups (all P<.05), including coating color (red, green, and blue), presence of tooth marks, coating crack ratio, moisture level, texture directionality, roughness, and contrast. The extreme gradient boosting model achieved the highest diagnostic performance with an area under the receiver operating characteristic curve of 0.84 (95% CI 0.78-0.90) and an area under the precision-recall curve above 0.70. Shapley additive explanations analysis indicated tongue color, moisture, and texture as key contributors. Conclusions: Our findings demonstrate the potential of tongue diagnosis in identifying pathogens responsible for acute respiratory tract infections at the time of admission. This approach holds significant clinical implications, offering the potential to reduce clinician workloads while improving diagnostic accuracy and the overall quality of medical care.

22 December 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
QCQianzi Che
Qianzi Che
TSTian Song
Tian Song
NLNing LIANG
Ning LIANG
JGJing Guo
Jing Guo
ZCZhao Chen
Zhao Chen
NSNannan Shi
Nannan Shi
Background: Although results from in vitro studies and small randomized controlled trials have shown positive effects of Dazhu hongjingtian injection (DZHJTI) on acute ischemic stroke (AIS), their generalizability to routine clinical practice remains to be established. Objective: The primary aim of this study is to evaluate the effectiveness of DZHJTI treatment for AIS with regard to changes in the stroke-related neurological deficit from baseline to outpatient follow-up, mortality, subsequent vascular events, disability, and traditional Chinese medicine syndrome in real-world clinical settings. By monitoring for adverse events or significant changes in vital signs and laboratory parameters, we also aim to assess the safety of DZHJTI. Methods: This prospective, multicenter cohort study plans to enroll 2000 patients with AIS within 14 days of symptom onset from 30 hospitals across China. Eligible patients will be followed up for 6 months after initiating medication treatments. The primary outcome will be the change in the National Institute of Health Stroke Scale score from baseline to outpatient follow-up. The secondary outcomes include overall mortality, stroke recurrence, new-onset major vascular events, global disability, and improvement of traditional Chinese medicine syndrome in 6 months. Adverse events or clinically significant changes in vital signs and laboratory parameters, regardless of the severity, will be recorded during the trial to assess the safety of DZHJTI. An augmented inverse propensity weighted estimator will be used to reduce variability and improve accuracy in average treatment effects estimation. Results: The clinical trial registration was approved in October 2022, and the recruitment and enrollment of participants started in November 2022. The study’s outcomes are expected to be published in 2025 in reputable, peer-reviewed health-related research journals. Conclusions: This real-world cohort study is the first to assess the effectiveness and safety of DZHJTI in treating AIS. It may provide additional clinical evidence, including the duration of response, long-term drug effectiveness, and subgroup efficacy data. The study results will be valuable for clinicians and patients seeking optimal treatment for AIS and could lead to better use of DZHJTI and improved patient outcomes. Trial Registration: ITMCTR ITMCTR2022000005; http://tinyurl.com/554ns8m5 International Registered Report Identifier (IRRID): DERR1-10.2196/52447

8 May 2020 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
QCQianzi Che
Qianzi Che
YZYan Zhang
Yan Zhang
JWJianan Wang
Jianan Wang
ZWZheng Wan
Zheng Wan
XFXianghua Fu
Xianghua Fu
YHYong Huo
Yong Huo
Aims We aimed to investigate the relationship between glycemic status and coronary artery disease (CAD) extent and severity in ST‐elevation myocardial infarction (STEMI) patients, and further examine whether diabetic patients could benefit from glycosylated hemoglobin (HbA1c) below the recommended level. Methods Consecutive STEMI patients admitted in 2015–2017 across 244 hospitals in China STEMI Care Project‐2. We conducted a cross‐sectional study comprising 8370 participants with a record of HbA1c testing after admission. CAD extent and severity was assessed by admission heart rate (AHR), Killip classification, and the number of stenosed vessels based on the coronary angiogram (CAG). Results Diabetic patients showed a higher risk for higher Killip class, admission tachycardia (AHR≥100 beats per minute) and multi‐vessel CAD (MVD, presence of left main and/or triple vessel disease). Likewise, HbA1c level was significantly associated with CAD extent and severity. While dividing diabetic patients according to general HbA1c targets (HbA1c ≤6.5, 6.5–7.0, and ≥7.0%), diabetic patients with HbA1c ≤6.5% showed a 1.30‐fold higher risk for MVD (adjusted odds ratio [aOR] 1.30, 95% CI: 1.05‐1.62). In stratified analysis, the association was even stronger in patients with hypertension (aOR 1.41, 95% CI: 1.08‐1.86) or hyperlipidemia (aOR 1.57, 95% CI: 1.17‐2.12). Conclusions HbA1c level is independently correlated with CAD extent and severity in STEMI patients. HbA1c below generally recommended levels may still increase the risk of CAD progression, especially for diabetic patients with hypertension or hyperlipidemia.

9 April 2024 in Journal of Evidence-Based Medicine
Verified
Journal Article
Closed access
QCQianzi Che
Qianzi Che
RHRuili Huo
Ruili Huo
CZChen Zhao
Chen Zhao
WYWei Yang
Wei Yang
XXXinghua Xiang
Xinghua Xiang
LHLuqi Huang
Luqi Huang